

# 1 Neutralization of VOCs including Delta one year post COVID-19 or 2 vaccine

3  
4 Sebastian Havervall<sup>#</sup>, MD<sup>1</sup>, Ulrika Marking<sup>#</sup>, MD<sup>1</sup>, Max Gordon, MD, PhD<sup>1</sup>, Henry Ng,  
5 MMSc<sup>1,2</sup>, Nina Greilert-Norin, RN<sup>1</sup>, Sarah Lindbo, PhD<sup>3</sup>, Kim Blom, PhD<sup>4</sup>, Peter Nilsson,  
6 PhD<sup>3</sup>, Mia Phillipson, PhD<sup>2</sup>, Jonas Klingström, PhD<sup>4,5</sup>, Sara Mangsbo, PhD<sup>6</sup>, Mikael Åberg,  
7 PhD<sup>7</sup>, Sophia Hober<sup>#</sup>, PhD<sup>3</sup> and Charlotte Thålin<sup>#</sup>, MD, PhD<sup>1</sup>

8  
9 1. Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm,  
10 Sweden

11 2. Department of Medical Cell Biology and Science for Life Laboratory, Uppsala University,  
12 Uppsala, Sweden

13 3. Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm,  
14 Sweden

15 4. Public Health Agency of Sweden, Solna, Sweden

16 5. Centre for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet,  
17 Stockholm, Sweden

18 6. Department of Pharmaceutical Biosciences and Science for Life Laboratory, Uppsala  
19 University, Uppsala, Sweden

20 7. Department of Medical Sciences, Clinical Chemistry and Science for Life Laboratory,  
21 Uppsala University, Uppsala, Sweden

22

23 # These authors contributed equally

24

25 **Keywords:** SARS-CoV-2; COVID-19; neutralizing antibodies; variants of concern; delta;  
26 immunity; vaccine

27

28

29 **Corresponding author:**

30 Charlotte Thålin, MD, PhD

31 Karolinska institutet, Danderyd hospital

32 18288 Stockholm, Sweden

33 Phone: +46 812355000,

34 Mail: [charlotte.thalin@sll.se](mailto:charlotte.thalin@sll.se)

35

36 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

37 **Abstract**

38 **Background:** SARS-CoV-2 variants, such as Alpha, Beta, Gamma and Delta, are raising  
39 concern about the efficiency of neutralizing antibodies (NAb) induced by wild-type infection or  
40 vaccines based on the wild-type spike.

41

42 **Methods:** We determined IgG and NAb against SARS-CoV-2 variants one year following  
43 mild wild-type infection (n=104) and two-dose regimens with BNT162b2 (BNT/BNT) (n=67),  
44 ChAdOx1 (ChAd/ChAd) (n=82), or heterologous ChAdOx1 followed by BNT162b2  
45 (ChAd/BNT) (n=116).

46

47 **Findings:** Wild type spike IgG and NAb remained detectable in 80% (83/104) of  
48 unvaccinated participants one year post mild infection. The neutralizing capacity was similar  
49 against wild type (reference), Alpha (0.95 (0.92-0.98) and Delta 1.03 (0.95-1.11) but  
50 significantly reduced against Beta (0.54 (0.48-0.60)) and Gamma 0.51 (0.44-0.61). Similarly,  
51 BNT/BNT and ChAd/ChAd elicited sustained capacity against Alpha and Delta (1.01 (0.78-  
52 1.31) and 0.85 (0.64-1.14)) and (0.96 (0.84-1.09) and 0.82 (0.61-1.10) respectively), with  
53 reduced capacity against Beta (0.67 (0.50-0.88) and 0.53 (0.40-0.71)) and Gamma (0.12  
54 (0.06-0.27) and 0.54 (0.37-0.80)). A similar trend was found following ChAd/BNT (0.74 (0.66-  
55 0.83) and 0.70 (0.50-0.97) against Alpha and Delta and 0.29 (0.20-0.42) and 0.13 (0.08-0.20)  
56 against Beta and Gamma).

57

58 **Interpretation:** Persistent neutralization of the wide-spread Alpha and Delta variants one  
59 year after wild-type infection may aid vaccine policy makers in low-resource settings when  
60 prioritizing vaccine supply. The reduced capacity of neutralizing Beta and Gamma strains,  
61 but not the Alpha and Delta strains following both infection and three different vaccine  
62 regimens argues for caution against Beta and Gamma-exclusive mutations in the efforts to  
63 optimize next generation SARS-CoV-2 vaccines.

64

65 **Funding:** A full list of funding bodies that contributed to this study can be found in the  
66 Acknowledgements section

67

68

## 69 **Introduction**

70 Increasing data support that neutralizing antibodies following SARS-CoV-2 infection provide  
71 a durable protection against reinfection (1-7), and vaccines have been shown effective in  
72 constraining hospitalization and deaths associated with SARS-CoV-2 infection (8-11).  
73 However, emerging SARS-CoV-2 variants are raising concerns. Viral variants of concern  
74 (VOC) with increased transmissibility, such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma)  
75 and B.1.617.2 (Delta), entail spike protein mutations conferring a fitness advantage affecting  
76 its biology, infectivity, transmissibility, and antigenicity (Figure 1). Spike alterations may  
77 enable immune escape, specially voiced when it comes to the B.1.351 (Beta) and P1  
78 (Gamma) VOC. Both display three mutations in the RBD region and particularly related to the  
79 E484K mutation, which has been shown to reduce antibody binding and neutralization (12).  
80 Assessing the efficiency of humoral immunity following wild-type infection and current  
81 vaccines against these globally spreading VOCs is important, both for understanding SARS-  
82 CoV-2 virulence and for the optimization of next generation SARS-CoV-2 vaccines (13-21).  
83 Using a high-throughput spike-specific IgG and pseudoneutralization assay, we determined  
84 the SARS-CoV-2 IgG antibody levels and neutralization capacity against the wild-type virus  
85 and VOCs one year following SARS-CoV-2 wild-type infection or following three different  
86 vaccine regimens employing the BNT162b2 (Comirnaty, Pfizer-BioNTech) and ChAdOx1  
87 nCoV-19 (Vaxzevria, AstraZeneca) vaccines.

88

## 89 **Methods**

90 The COMMUNITY (COVID-19 Biomarker and Immunity) study (22, 23) investigates immune  
91 responses after COVID-19 infection and vaccination. Between April 15 and May 8, 2020,  
92 2149 healthcare workers (HCW) at Danderyd Hospital, Stockholm, Sweden were included.  
93 All study participants are invited for repeated blood samplings every four months. Serology  
94 was performed using two assays; a multiplex antigen bead assay (FlexMap3D, Luminex  
95 Corp) (24) measuring spike-specific IgG and the V-PLEX SARS-CoV-2 Panel 13 (Meso  
96 Scale Diagnostics, USA) measuring spike-specific IgG and their neutralizing capacity  
97 (pseudo-neutralizing spike-ACE2 assay) against SARS-CoV-2 wild-type and variants B.1.1.7  
98 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta). Clinical sensitivity, specificity,  
99 and cut-off values for the wild-type strain for both MSD assays (K15463U (IgG), K15466U  
100 (ACE2)) were established by ROC analysis of 200 commercially sourced pre-2109 healthy  
101 adults and 214 PCR-confirmed COVID-19 patients by the manufacturer. Values for each  
102 assay can be obtained from kit insert Appendix G found at the manufacturer's homepage  
103 <http://www.mesoscale.com>.

104

105 This sub study included one group with all study participants that were confirmed SARS-  
106 CoV-2 Spike IgG positive by both assays at study inclusion, who attended all follow-ups and  
107 who were not yet vaccinated by the 12-month follow-up. All participants reported mild  
108 COVID-19 symptoms, and none were hospitalized. Blood samples were also obtained from  
109 three groups of vaccinated individuals: all participants who received two doses of BNT162b2  
110 vaccine (BNT x 2; median dose interval 21 days (IQR 21-21), two doses of ChAdOx1 nCoV-  
111 19 vaccine (ChAd x 2; median dose interval 81.5 days (IQR 77-84)) or a prime dose of  
112 ChAdOx1 nCoV-19 vaccine and booster dose with BNT162b2 vaccine (ChAd + BNT; median  
113 dose interval 90 days (IQR 86-94)). Blood samples were collected 30-55 days following the  
114 BNT x 2 regimens, and 14-22 days following regimens with ChAd priming. The study was  
115 approved by the Swedish Ethical Review Authority (dnr 2020-01653), and written informed  
116 consent was obtained from all study participants.

117

### 118 *Statistical analysis*

119 We used mixed effect modelling with subject id as random effect where the outcome during  
120 modelling was converted using the log<sub>2</sub>-function. Interaction between strain and timespans  
121 was tested in two subsequent steps, baseline vs any other follow-up, and within the follow-  
122 ups. The models were compared using ANOVA. Analyses were performed in R version 4.1.0  
123 with nlme-package (v. 3.1.152). The estimates were compared using the contrast-package  
124 (v. 0.22). Each model was adjusted for age and sex. Correlation analysis was performed  
125 using Spearman.

126

### 127 **Role of the funding source**

128 The funders had no role in the design and conduct of the study; collection, management,  
129 analysis, and interpretation of the data; preparation, review, or approval of the manuscript;  
130 and decision to submit the manuscript for publication.

131

### 132 **Results**

133 A total of 104 study participants who were confirmed spike IgG positive at study inclusion  
134 and attended all four-month follow-ups remained unvaccinated at the 12-month follow-up  
135 (median age 42 (IQR 31.75-51.25), 88% female). In line with prior reports (3, 4, 25) the levels  
136 of both spike binding IgG and neutralizing antibodies (NAb) against the SARS-CoV-2 wild-  
137 type strain declined over the first few months, but thereafter remained stable, (Fig 2 A-B),  
138 with similar trends for all SARS-CoV-2 VOCs (Table S1). High spike IgG and NAb levels at  
139 baseline correlated with high levels 12 months post infection against the wild-type virus and  
140 all four VOCs (all  $r > 0.5$  and maximum  $p < 0.0001$ ). Wild-type spike IgG remained detectable  
141 in 91% (95/104), 84% (87/104) and 80% (83/104) of the participants at the 4-, 8- and 12-

142 month follow-up, respectively, with corresponding Wild-type NAb being 96% (100/104), 93%  
143 (97/104) and 91% (95/104).

144  
145 Differences in neutralizing capacity against the SARS-CoV-2 wild-type and VOCs using  
146 samples taken 12 months post infection was determined by quantile regression adjusting for  
147 age and sex. With the neutralizing capacity against the SARS-CoV-2 wild-type strain as the  
148 reference, the capacity of the antibodies induced by the natural infection of the wild-type  
149 virus was only slightly reduced against the B.1.1.7 (Alpha) and similar against the B.1.617.2  
150 (Delta) strain. There was, however, a notable and reduction against the B.1.351 (Beta) and  
151 P.1 (Gamma) strains (Figure 2C, 3 and Table S2).

152  
153 We next investigated differences in neutralizing capacity against the SARS-CoV-2 wild-type  
154 and VOCs following vaccination with either two doses BNT162b2 vaccine (n=67, median age  
155 52 (IQR 41-59), 84% female), two doses ChAdOx1 nCoV-19 vaccine (n=82, median age 51  
156 (IQR 42-57), 88% female) or a prime dose of ChAdOx1 nCoV-19 vaccine and booster dose  
157 with BNT162b2 vaccine (n=116, median age 50 (IQR 40-56), 92% female). Similar to the  
158 responses observed 12 months post infection, the neutralizing capacity following the  
159 BNT/BNT and ChAd/ChAd vaccine regimens were similar against the B.1.1.7 (Alpha),  
160 B.1.617.2 (Delta) and wild-type strains. However, there was a reduction against the B.1.351  
161 (Beta) and P.1 (Gamma) strains (Figure 2 D-E, 3 and Table S2). The ChAd/BNT vaccine  
162 regimen elicited antibodies capable of similar neutralization against the B.1.617.2 (Delta) and  
163 the wild-type strain, but with slightly lower neutralizing capacity against the B.1.1.7 (Alpha)  
164 strain. NAb titers against the B.1.351 (Beta) and P.1 (Gamma) strains were, as with the two  
165 other vaccine regimens, significantly reduced (Figure 2F and 3 and Table S2).

## 166 167 **Discussion**

168 Our results demonstrate initial reductions but thereafter stable SARS-CoV-2 IgG levels over  
169 12 months following mild SARS-CoV-2 infection. Circulating and readily detectable  
170 antibodies are crucial in the assessment and diagnosis of prior infection both on an individual  
171 and population-based level. We furthermore show that these antibodies display neutralizing  
172 abilities against the B.1.1.7 (Alpha) and B.1.617.2 (Delta) strains similar to those against the  
173 wild-type strain, and that this capacity is maintained over time, implying a robust immunity  
174 also against these now globally spreading strains. Notably, neutralizing capacity was,  
175 however, significantly reduced against the B.1.351 (Beta) and P.1 (Gamma) strains.

176 The two vaccines used in the studied regimens are both based on the wild-type SARS-CoV-2  
177 spike protein. We found that these three vaccine regimens elicited a similar response as

178 infection with the wild-type strain. Although the virulence of a certain VOC as well as the level  
179 of evoked immune protection is dependent on a multitude of features, it is highly influenced  
180 by the interaction between the viral spike protein and the host ACE2 receptor. A VOC with  
181 higher affinity to ACE2 potentially needs fewer virions to be infective. Further, escape  
182 mutants able to evade the immune system might appear as the immunity develops globally.  
183 To date, there is published data showing a higher affinity to ACE2 for two (B.1.1.7 (Alpha)  
184 and B.1.351 (Beta)) of the four VOCs (26), while data regarding the other two VOCs (P.1  
185 (Gamma), and B.1.617.2 (Delta)) is still missing. Our data indicate no loss of neutralisation of  
186 lineage B.1.1.7 (Alpha), suggesting that the higher transmissibility depends on viral  
187 characteristics such as the reported higher affinity gained by the N501Y. The additional  
188 mutations in positions 417 and 484 are affecting the neutralizing possibility where a threonine  
189 in position 417 (in P.1 (Gamma)) appears to give a negative effect for the BNT vaccine  
190 (Figure 1 and 3). The higher transmissibility of lineage B.1.617.2 (Delta) does not seem to be  
191 based on a lower antibody protection due to the two mutations in RBD alone. However, a  
192 higher rate of proliferation has been reported (27) for this VOC. The major concern regarding  
193 this VOC does not seem to stem from immune escape but could instead be due to other  
194 improved fitness characteristics.

195 So far, the E484 mutation has been reported to affect antibody binding and neutralization  
196 (28) and as such, both B.1.351 (Beta) and P.1 (Gamma) would be at risk of escaping  
197 immune control induced by the wild-type strain or current vaccines, which is corroborated by  
198 our IgG and Nab results.

199  
200 Limitations of this study include the observational and single-center design and the large  
201 portion of women. Strengths include the long follow-up and different vaccine regimes within  
202 the same study protocol along with the baseline sample opportunity against the wild-type and  
203 VOC strains.

204  
205 Our findings of long-lasting neutralization of the widely spreading B.1.1.7 (Alpha) and  
206 B.1.617.2 (Delta) variants one year after wild type infection may aid vaccine policy makers in  
207 low-resource settings when prioritizing limited vaccine supply. Furthermore, the globally  
208 reduced capacity of neutralizing B.1.351 (Beta) and P.1 (Gamma) strains, but not the B.1.1.7  
209 (Alpha) and B.1.617.2 (Delta) strains following both infection and three different vaccine  
210 regimens argues for caution against B.1.351 (Beta) and P.1 (Gamma)-exclusive spike  
211 protein mutations in the efforts to optimize next generation SARS-CoV-2 vaccines.

212

213



## 214 **Acknowledgements**

215 This work was funded by Jonas & Christina af Jochnick foundation; Lundblad family  
216 foundation; Region Stockholm; Knut and Alice Wallenberg foundation; Science for Life  
217 Laboratory (SciLifeLab); Erling-Persson family foundation; CIMED and the Swedish  
218 Research Council.

219

## 220 **Conflict of Interest**

221 SoH has participated on Astra Zeneca COVID-19 SCG Virtual Advisory Board. Otherwise,  
222 the authors declare no competing interests.

223

## 224 **Author contribution**

225 SeH, UM, and CT had full access to all the data in the study and takes responsibility for the  
226 integrity of the data and the accuracy of the data analysis.

227 SeH, UM, SoH, and CT designed the study, and drafted the manuscript. MG made the  
228 statistical analyses. NG, HN, MÅ conducted the analysis and the administrative and material  
229 support. SeH, UM, SL, KB, PN, SM, JK, MP, MÅ, SoH, PN, CT interpreted the data, and all  
230 authors critically revised the manuscript. SoH, PN, CT obtained funding. MP, MÅ, SoH, CT  
231 supervised. All authors had final responsibility for the decision to submit for publication.

232

## 233 **Data sharing**

234 The anonymized datasets generated during and/or analyzed during the current study are  
235 available from the corresponding author on reasonable request.

236

237

## 238 **References**

- 239 1. Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang M-L, et al.  
240 Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery  
241 Vessel Outbreak with a High Attack Rate. *Journal of Clinical Microbiology*. 2020;58(11):e02107-20.
- 242 2. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et al.  
243 A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of  
244 protection, and association with severity. *Nature Communications*. 2020;11(1):4704.
- 245 3. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust  
246 neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science*. 2020.
- 247 4. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to  
248 SARS-CoV-2 assessed for up to 8 months after infection. *Science*. 2021;371(6529).
- 249 5. Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan WH, Chiu SS, et al. Neutralizing  
250 antibody titres in SARS-CoV-2 infections. *Nat Commun*. 2021;12(1):63.
- 251 6. Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al. Naturally  
252 enhanced neutralizing breadth against SARS-CoV-2 one year after infection. *Nature*.  
253 2021;595(7867):426-31.

- 254 7. Turner JS, Kim W, Kalaidina E, Goss CW, Rauseo AM, Schmitz AJ, et al. SARS-CoV-2  
255 infection induces long-lived bone marrow plasma cells in humans. *Nature*. 2021.
- 256 8. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and  
257 efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four  
258 randomised controlled trials in Brazil, South Africa, and the UK. *Lancet*. 2021;397(10269):99-111.
- 259 9. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and  
260 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New England Journal of Medicine*.  
261 2020;383(27):2603-15.
- 262 10. Shrotri M, Krutikov M, Palmer T, Giddings R, Azmi B, Subbarao S, et al. Vaccine  
263 effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in  
264 residents of long-term care facilities in England (VIVALDI): a prospective cohort study. *The Lancet*  
265 *Infectious Diseases*.
- 266 11. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA  
267 Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *New England Journal of Medicine*.  
268 2021;384(15):1412-23.
- 269 12. Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, et al.  
270 Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect  
271 recognition by polyclonal human plasma antibodies. *Cell Host Microbe*. 2021;29(3):463-76.e6.
- 272 13. Neuzil KM. Interplay between Emerging SARS-CoV-2 Variants and Pandemic Control.  
273 *New England Journal of Medicine*. 2021;384(20):1952-4.
- 274 14. Gómez CE, Perdiguero B, Esteban M. Emerging SARS-CoV-2 Variants and Impact in  
275 Global Vaccination Programs against SARS-CoV-2/COVID-19. *Vaccines (Basel)*. 2021;9(3).
- 276 15. Wang P, Casner RG, Nair MS, Wang M, Yu J, Cerutti G, et al. Increased resistance of  
277 SARS-CoV-2 variant P.1 to antibody neutralization. *Cell Host Microbe*. 2021;29(5):747-51.e4.
- 278 16. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al.  
279 Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature*. 2021.
- 280 17. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19  
281 Vaccine against the B.1.1.7 and B.1.351 Variants. *N Engl J Med*. 2021.
- 282 18. Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et al. Efficacy of NVX-  
283 CoV2373 Covid-19 Vaccine against the B.1.351 Variant. *N Engl J Med*. 2021;384(20):1899-909.
- 284 19. Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the  
285 ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. *N Engl J Med*. 2021;384(20):1885-  
286 98.
- 287 20. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al.  
288 Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *New England Journal of*  
289 *Medicine*. 2021.
- 290 21. Krause PR, Fleming TR, Longini IM, Peto R, Briand S, Heymann DL, et al. SARS-CoV-2  
291 Variants and Vaccines. *New England Journal of Medicine*. 2021;385(2):179-86.
- 292 22. Rudberg AS, Havervall S, Manberg A, Jernbom Falk A, Aguilera K, Ng H, et al. SARS-  
293 CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. *Nat Commun*.  
294 2020;11(1):5064.
- 295 23. Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, et al. Symptoms  
296 and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers.  
297 *JAMA*. 2021.
- 298 24. Hober S, Hellström C, Olofsson J, Andersson E, Bergström S, Jernbom Falk A, et al.  
299 Systematic evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex  
300 serological COVID-19 assay. *Clinical & Translational Immunology*. 2021;10(7):e1312.
- 301 25. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal  
302 observation and decline of neutralizing antibody responses in the three months following SARS-CoV-  
303 2 infection in humans. *Nature Microbiology*. 2020;5(12):1598-607.



- 304 26. Ramanathan M, Ferguson ID, Miao W, Khavari PA. SARS-CoV-2 B.1.1.7 and B.1.351  
305 spike variants bind human ACE2 with increased affinity. *The Lancet Infectious Diseases*.  
306 2021;21(8):1070.
- 307 27. Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DdS, Mishra S, et al. Genomics  
308 and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. *Science*. 2021;372(6544):815-21.
- 309 28. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-  
310 CoV-2 variants, spike mutations and immune escape. *Nature Reviews Microbiology*. 2021;19(7):409-  
311 24.
- 312 29. Wrobel AG, Benton DJ, Xu P, Roustan C, Martin SR, Rosenthal PB, et al. SARS-CoV-2  
313 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects.  
314 *Nature Structural & Molecular Biology*. 2020;27(8):763-7.

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340


341

342

343

344 **Figures**

345



346

347

348 **Figure 1.** A top view of the structure of a furin-cleaved spike protein of SARS-CoV-2 is  
349 shown (6ZGG) with the receptor binding domain (RBD) of the three chains colored in light  
350 blue. Positions of RBD that are mutated in the four most common VOCs are colored in red.  
351 RBD of the B chain is shown in the erected state (29). The different mutations included in the  
352 four VOCs are listed in the figure.







353

354


355

356

357



359 **Figure 2. A-B.** Wild type (WT) spike-specific IgG and neutralizing antibodies (AU/ml) after  
 360 SARS-CoV-2 WT infection at baseline and at the 4-, 8-, and 12-months follow-up visit.  
 361 **C-F.** Neutralizing antibodies (AU/ml) for wild type (WT) and B.1.1.7 (Alpha), B.1.351 (Beta),  
 362 P.1 (Gamma) and B.1.617.2 (Delta) after **C:** 12 months infection, **D:** two doses BNT162b2  
 363 vaccine, **E:** two doses ChAdOx1 nCoV-19, **F:** heterologous vaccine regimen with ChAdOx1  
 364 nCoV-19 and BNT162b2. Black lines represent medians. Dashed grey lines represent cut-off  
 365 values for wild type as determined by the manufacturer: IgG = 1960, neutralization = 0.533.  
 366 WT; Wild type, BNT; BNT162b2 vaccine, ChAd; ChAdOx1 nCoV-19; m; months, ab;  
 367 antibodies  
 368  
 369  
 370



371  
 372  
 373 **Figure 3.** Forest plot of regression output for strain type neutralization. Estimates are  
 374 multiplicative, i.e. 0.5 corresponds to a 50% reduction in antibody response in relation to the  
 375 wild-type strain. The model is a mixed effect quantile regression for the median. BNT;  
 376 BNT162b2 vaccine, ChAd; ChAdOx1 nCoV-19  
 377  
 378  
 379  
 380  
 381  
 382  
 383  
 384

385 **Supplementary data**

386

387 **Table S1**

	Baseline		4m		8m		12m	
	Median	IQR	Median	IQR	Median	IQR	Median	IQR
IgG (kAU/ml)								
Wild type	12.6	(6.3-23.3)	6.0	(3.6-10.0)	5.5	(2.6-8.3)	4.0	(2.1-7.6)
Alpha (B.1.1.7)	9.9	(5.4-17.5)	5.9	(3.3-9.9)	4.9	(2.6-8.1)	4.0	(2.2-7.2)
Beta (B.1.351)	5.4	(3.2-11.2)	3.7	(2.2-6.4)	3.8	(1.9-6.5)	2.8	(1.6-5.4)
Delta (B.1.617.2)	4.9	(2.8-12.5)	3.5	(2.1-6.1)	3.5	(1.8-5.8)	2.6	(1.5-5.1)
Gamma (P.1)	6.7	(3.1-14.0)	3.5	(2.1-6.4)	3.7	(1.7-6.3)	2.6	(1.3-5.0)
Neutralizing ab (AU/ml)								
Wild type	3.6	(2.3-7.9)	1.7	(1.2-2.6)	1.3	(0.9-1.7)	1.1	(0.8-1.5)
Alpha (B.1.1.7)	2.8	(2.0-6.1)	1.5	(1.1-2.5)	1.2	(0.9-1.8)	1.0	(0.7-1.6)
Beta (B.1.351)	1.1	(0.8-2.2)	0.7	(0.5-1.1)	0.6	(0.4-0.9)	0.5	(0.4-0.9)
Delta (B.1.617.2)	3.7	(2.1-7.6)	1.6	(0.9-2.3)	1.1	(0.6-1.7)	1.2	(0.7-1.7)
Gamma (P.1)	1.2	(0.8-2.4)	0.8	(0.4-1.3)	0.5	(0.1-0.9)	0.6	(0.4-0.9)

Median and interquartile range for antibody response for SARS-CoV-2 variants (n=104)

388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421

422 **Table S2**  
423

	<b>Est.</b>	<b>CI</b>
<b>Natural infection</b>		
One year		
Wild-type	1.00	(reference)
Alpha (B.1.1.7)	0.95	(0.92 - 0.98)
Beta (B.1.351)	0.54	(0.48 - 0.60)
Gamma (P.1)	0.51	(0.44 - 0.61)
Delta (B.1.617.2)	1.03	(0.95 - 1.11)
<b>Vaccine regimen</b>		
BNT/BNT		
Wild-type	1.00	(reference)
Alpha (B.1.1.7)	1.01	(0.78 - 1.31)
Beta (B.1.351)	0.67	(0.50 - 0.88)
Gamma (P.1)	0.12	(0.06 - 0.27)
Delta (B.1.617.2)	0.85	(0.64 - 1.14)
ChAd/BNT		
Wild-type	1.00	(reference)
Alpha (B.1.1.7)	0.74	(0.66 - 0.83)
Beta (B.1.351)	0.29	(0.20 - 0.42)
Gamma (P.1)	0.13	(0.08 - 0.20)
Delta (B.1.617.2)	0.70	(0.50 - 0.97)
ChAd/ChAd		
Wild-type	1.00	(reference)
Alpha (B.1.1.7)	0.96	(0.84 - 1.09)
Beta (B.1.351)	0.53	(0.40 - 0.71)
Gamma (P.1)	0.54	(0.37 - 0.80)
Delta (B.1.617.2)	0.82	(0.61 - 1.10)

Regression output for neutralization against different viral strains. Comparisons are conducted within the separate groups, with neutralization against wild-type within each group as reference. Estimates are multiplicative, i.e. 0.5 corresponds to a 50% reduction in antibody response. Each separate group is a quantile regression model for the median with mixed effect.